Solventum Corporation $SOLV Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management cut its Solventum stake by 71.7% in the second quarter, selling 24,604 shares and retaining 9,688 shares valued at approximately $747,000.
• Analyst sentiment remains positive: Solventum received several price-target increases and upgrades, with a consensus rating of “Moderate Buy” and an average target price of $92.80.
• Solventum exceeded quarterly expectations, reporting $2.55 in EPS versus a $1.91 consensus estimate and $2.21 billion in revenue, up 2.2% year over year.

Wellington Management Group LLP trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 71.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,688 shares of the company's stock after selling 24,604 shares during the period. Wellington Management Group LLP's holdings in Solventum were worth $747,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. BOKF NA boosted its position in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company's stock worth $160,000 after buying an additional 141 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Solventum by 23.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company's stock worth $60,000 after acquiring an additional 142 shares during the period. NewEdge Advisors LLC boosted its holdings in Solventum by 2.2% in the 1st quarter. NewEdge Advisors LLC now owns 6,707 shares of the company's stock worth $438,000 after acquiring an additional 144 shares during the period. Deseret Mutual Benefit Administrators grew its position in Solventum by 39.5% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company's stock valued at $41,000 after acquiring an additional 146 shares in the last quarter. Finally, HB Wealth Management LLC raised its stake in shares of Solventum by 3.5% during the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company's stock valued at $280,000 after purchasing an additional 147 shares during the period.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. BTIG Research boosted their target price on shares of Solventum from $91.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. UBS Group lifted their price target on shares of Solventum from $95.00 to $101.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wall Street Zen upgraded shares of Solventum from a "hold" rating to a "buy" rating in a report on Saturday. Stifel Nicolaus upped their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.80.

Solventum Trading Down 0.3%

SOLV opened at $87.43 on Friday. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $94.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market capitalization of $14.88 billion, a PE ratio of 10.69, a P/E/G ratio of 1.37 and a beta of 0.61. The firm's fifty day moving average price is $85.15 and its 200 day moving average price is $76.55.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm's revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period last year, the business earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts expect that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.